MarketCap
Facebook
X
TelegramQuarterly report 2025-Q4
added 02-11-2026
Organovo Holdings Operating Income 2011-2026 | ONVO
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Organovo Holdings
| 2025 | 2024 | 2023 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -12.6 M | -15.1 M | -17.7 M | -16.8 M | -21.5 M | -27.3 M | -35.3 M | -38.6 M | -38.6 M | -30.3 M | -20.6 M | - | -9.32 M | -2.3 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.3 M | -38.6 M | -22 M |
Quarterly Operating Income Organovo Holdings
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.75 M | -2.64 M | -2.92 M | - | -3.47 M | -2.61 M | -3.39 M | - | -3.68 M | -4.12 M | -4.2 M | - | -3.36 M | -3.35 M | -3.24 M | - | -3.5 M | -9.57 M | -6.07 M | - | -2.49 M | -2.49 M | -8.95 M | -2.79 M | -5.23 M | -5.23 M | -6.83 M | -6.52 M | -6.53 M | -6.53 M | -6.01 M | - | -7.91 M | -9.58 M | -10.2 M | - | -9.63 M | -27.9 M | -18.3 M | - | -10.5 M | -30.2 M | -19.7 M | - | -6.96 M | -22.3 M | -15.4 M | - | -4.63 M | -14 M | -9.34 M | -4.02 M | -2.92 M | -7.99 M | -5.07 M | -1.33 M | - | -622 K | -474 K | -492 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -474 K | -30.2 M | -7.3 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
-32.8 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Brainsway Ltd.
BWAY
|
-5 M | $ 23.08 | 1.7 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 29.14 | -3.75 % | $ 326 M |  China |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
BioNano Genomics
BNGO
|
-104 M | $ 1.1 | 0.46 % | $ 1.4 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M | Israel |
 |
Co-Diagnostics
CODX
|
-42.7 M | - | - | $ 79.8 M | USA |
 |
DarioHealth Corp.
DRIO
|
-56.2 M | $ 11.38 | 1.16 % | $ 323 M | Israel |
 |
DexCom
DXCM
|
912 M | $ 70.29 | 8.0 % | $ 27.4 B | USA |
 |
Celcuity
CELC
|
-113 M | $ 103.65 | -1.16 % | $ 4.09 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | $ 32.89 | 3.09 % | $ 914 M | USA |
 |
Danaher Corporation
DHR
|
4.86 B | $ 211.14 | -1.74 % | $ 154 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.35 B | $ 205.13 | -0.82 % | $ 22.8 B | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 23.24 | 1.18 % | $ 703 M | USA |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
CareDx, Inc
CDNA
|
-203 M | $ 19.6 | 2.62 % | $ 1.05 B | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
Interpace Biosciences
IDXG
|
8.11 M | $ 1.85 | - | $ 8.12 M | USA |
 |
Exact Sciences Corporation
EXAS
|
-876 M | $ 103.32 | 0.09 % | $ 19.1 B | USA |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
Lantheus Holdings
LNTH
|
457 M | $ 68.71 | -0.02 % | $ 4.75 B | USA |
 |
Guardant Health
GH
|
-444 M | $ 104.76 | 1.95 % | $ 12.9 B | USA |
 |
QIAGEN N.V.
QGEN
|
97.7 M | - | - | $ 10.6 B |  Niderland |
 |
National Research Corporation
NRC
|
40 M | $ 12.09 | -5.81 % | $ 297 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Charles River Laboratories International
CRL
|
227 M | $ 160.2 | 0.91 % | $ 8.23 B | USA |
 |
IDEXX Laboratories
IDXX
|
1.13 B | $ 627.58 | 1.68 % | $ 51.8 B | USA |
 |
Illumina
ILMN
|
-833 M | $ 115.9 | 1.27 % | $ 18.4 B | USA |
 |
OPKO Health
OPK
|
-152 M | $ 1.24 | 2.48 % | $ 861 M | USA |
 |
IQVIA Holdings
IQV
|
2.2 B | $ 166.72 | -1.27 % | $ 30.2 B | USA |
 |
Natera
NTRA
|
-541 M | $ 204.66 | -1.53 % | $ 20.1 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 31.11 | -0.94 % | $ 20 B | Niderland |
|
Biodesix
BDSX
|
-34.5 M | $ 11.55 | 6.6 % | $ 1.5 B | USA |
 |
Personalis
PSNL
|
-68.3 M | $ 8.22 | -2.09 % | $ 487 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.09 B | $ 281.39 | 1.13 % | $ 23.6 B | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | $ 95.34 | 19.06 % | $ 7.86 B |  Irlanda |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.25 | 4.19 % | $ 5.17 M | USA |
 |
Bioventus
BVS
|
-81.7 M | $ 8.22 | 1.48 % | $ 515 M | USA |
 |
Medpace Holdings
MEDP
|
535 M | $ 429.09 | 3.14 % | $ 12.4 B | USA |